All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

JAKARTA trials: Does fedratinib provide a survival benefit in patients with MF?

During the EHA2021 Virtual Congress, the MPN Hub spoke with Claire Harrison, Guy’s and St Thomas’ NHS Foundation Trust, London, UK. We asked, Does fedratinib provide a survival benefit in patients with myelofibrosis (MF)?

JAKARTA trials: Does fedratinib provide a survival benefit in patients with MF?

Harrison discusses the JAKARTA phase III trial results, which led to the approval of fedratinib, a JAK2 inhibitor, as a first- and second-line treatment for patients with MF.

 

Share: